Back to results
US 2024/0173352 A1Published application
Cell-surface receptors responsive to loss of heterozygosity
OwnerCarl Alexander KAMB, Agnes HAMBURGER +1inventors
InventorsCarl Alexander KAMB, Agnes HAMBURGER, Han XU
Life of this patent
Estimating the term…
Abstract
The disclosure relates to systems of two engineered receptors each having a ligand binding domain, collectively designed to target cells identified by loss of heterozygosity and used to treat a disease or disorder, for example, cancer. The disclosure provides immune cells expressing two engineered receptors, methods of making same, and polynucleotides and vectors encoding same.
Claims30
An immune cell, comprising:
- a. a first engineered receptor, the first engineered receptor comprising a transmembrane region and an extracellular region, the extracellular region comprising a first ligand binding domain capable of specifically binding a first ligand;
- and
- b. a second engineered receptor, the second engineered receptor comprising a transmembrane region and an extracellular region, the extracellular region comprising a second ligand binding domain capable of specifically binding a second ligand,
- wherein binding of the first ligand binding domain to the first ligand activates or promotes activation of the immune cell by the first receptor, and
- wherein binding of the second ligand binding domain to the second ligand inhibits activation of the immune cell by the first receptor.
2 more elements
-6. (canceled)
-11. (canceled)
(canceled)
-17. (canceled)
(canceled)
-30. (canceled)
-57. (canceled)
-60. (canceled)
-65. (canceled)
-102. (canceled)
Dependencies are inferred from the claim text.